CO2022017903A2 - Compuestos de dihidroquinolinsulfonamida de ciclobutilo - Google Patents
Compuestos de dihidroquinolinsulfonamida de ciclobutiloInfo
- Publication number
- CO2022017903A2 CO2022017903A2 CONC2022/0017903A CO2022017903A CO2022017903A2 CO 2022017903 A2 CO2022017903 A2 CO 2022017903A2 CO 2022017903 A CO2022017903 A CO 2022017903A CO 2022017903 A2 CO2022017903 A2 CO 2022017903A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- dihydroquinolinesulfonamide
- cyclobutyl
- formula
- present
- Prior art date
Links
- PAPIDPZGJVSNRS-UHFFFAOYSA-N N-cyclobutyl-1,2-dihydroquinoline-2-sulfonamide Chemical class O=S(C1NC2=CC=CC=C2C=C1)(NC1CCC1)=O PAPIDPZGJVSNRS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010011224 Cough Diseases 0.000 abstract 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- -1 cyclobutyl dihydroquinolinesulfonamide compound Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000007803 itching Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037001P | 2020-06-10 | 2020-06-10 | |
| PCT/US2021/036896 WO2021252820A1 (en) | 2020-06-10 | 2021-06-10 | Cyclobutyl dihydroquinoline sulfonamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022017903A2 true CO2022017903A2 (es) | 2022-12-20 |
Family
ID=76797115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0017903A CO2022017903A2 (es) | 2020-06-10 | 2022-12-09 | Compuestos de dihidroquinolinsulfonamida de ciclobutilo |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US12240839B2 (https=) |
| EP (2) | EP4165024B1 (https=) |
| JP (2) | JP7739051B2 (https=) |
| KR (1) | KR20230022996A (https=) |
| CN (2) | CN119735588A (https=) |
| AR (1) | AR122592A1 (https=) |
| AU (1) | AU2021288696A1 (https=) |
| BR (1) | BR112022025201A2 (https=) |
| CA (1) | CA3183889A1 (https=) |
| CL (1) | CL2022003499A1 (https=) |
| CO (1) | CO2022017903A2 (https=) |
| CR (1) | CR20220631A (https=) |
| DK (1) | DK4165024T3 (https=) |
| ES (1) | ES3037072T3 (https=) |
| FI (1) | FI4165024T3 (https=) |
| HR (1) | HRP20251229T1 (https=) |
| HU (1) | HUE072945T2 (https=) |
| IL (2) | IL326793A (https=) |
| JO (1) | JOP20220334A1 (https=) |
| LT (1) | LT4165024T (https=) |
| MA (1) | MA59968B1 (https=) |
| MX (2) | MX2022015856A (https=) |
| PE (1) | PE20230860A1 (https=) |
| PL (1) | PL4165024T3 (https=) |
| PT (1) | PT4165024T (https=) |
| RS (1) | RS67268B1 (https=) |
| SI (1) | SI4165024T1 (https=) |
| SM (1) | SMT202500328T1 (https=) |
| TW (1) | TWI899251B (https=) |
| UY (1) | UY39263A (https=) |
| WO (1) | WO2021252820A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| HRP20260068T1 (hr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| US20240400544A1 (en) | 2021-06-04 | 2024-12-05 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| KR20240046891A (ko) * | 2021-08-12 | 2024-04-11 | 티와이케이 메디슨즈, 인코포레이티드 | 다환 화합물 및 그의 용도 |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3256248A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4412994A (en) | 1980-04-24 | 1983-11-01 | Interx Research Corporation | Mannich-base hydroxamic acid prodrugs, compositions and use |
| US5707985A (en) | 1995-06-07 | 1998-01-13 | Tanabe Seiyaku Co. Ltd. | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators |
| PA8444901A1 (es) | 1997-01-28 | 2000-05-24 | Hoffmann La Roche | Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios |
| CN1315836C (zh) | 2002-04-26 | 2007-05-16 | 奥索-麦克尼尔药品公司 | 用作雄激素受体调节剂的2－(喹诺酮基)－稠合杂环 |
| BRPI0406778A (pt) | 2003-01-17 | 2006-01-17 | Warner Lambert Co | Antagonistas de receptores de androgênio |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| WO2006117762A2 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Antimicrobial agents |
| MX2007014180A (es) | 2005-05-10 | 2008-01-14 | Vertex Pharma | Derivados biciclicos como moduladores de canales de iones. |
| CA2608599A1 (en) | 2005-05-16 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| CA2741024A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CN102471235A (zh) | 2009-07-11 | 2012-05-23 | 拜耳医药股份有限公司 | 利用环烷基的放射性标记方法 |
| CN102030780B (zh) * | 2010-10-26 | 2014-01-29 | 浙江大学 | 一种手性螺环磷酸和制备方法及其应用 |
| MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| US9012443B2 (en) | 2011-12-07 | 2015-04-21 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| WO2016124139A1 (zh) | 2015-02-04 | 2016-08-11 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| EA032928B1 (ru) | 2015-03-02 | 2019-08-30 | Эмджен Инк. | Бициклические кетосульфонамидные соединения |
| JP6903663B2 (ja) | 2015-12-18 | 2021-07-14 | アムジエン・インコーポレーテツド | アルキルジヒドロキノリンスルホンアミド化合物 |
| MX378012B (es) * | 2015-12-18 | 2025-03-10 | Amgen Inc | Compuestos de alquinil dihidroquinolina sulfonamida. |
| CN109563045B (zh) * | 2016-03-21 | 2022-08-23 | 斯克里普斯研究学院 | Pd(II)-催化的对映选择性β-亚甲基C(sp3)-H键活化 |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP2021195367A (ja) | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| KR20240046891A (ko) | 2021-08-12 | 2024-04-11 | 티와이케이 메디슨즈, 인코포레이티드 | 다환 화합물 및 그의 용도 |
| MX2024002176A (es) | 2021-08-19 | 2024-03-12 | Amgen Inc | Preparacion estereoselectiva de ciclobutano trans halo. |
-
2021
- 2021-05-31 JP JP2021090960A patent/JP7739051B2/ja active Active
- 2021-06-10 EP EP21737878.5A patent/EP4165024B1/en active Active
- 2021-06-10 CR CR20220631A patent/CR20220631A/es unknown
- 2021-06-10 RS RS20250992A patent/RS67268B1/sr unknown
- 2021-06-10 BR BR112022025201A patent/BR112022025201A2/pt unknown
- 2021-06-10 WO PCT/US2021/036896 patent/WO2021252820A1/en not_active Ceased
- 2021-06-10 MX MX2022015856A patent/MX2022015856A/es unknown
- 2021-06-10 SM SM20250328T patent/SMT202500328T1/it unknown
- 2021-06-10 US US17/633,151 patent/US12240839B2/en active Active
- 2021-06-10 AR ARP210101586A patent/AR122592A1/es unknown
- 2021-06-10 TW TW110121155A patent/TWI899251B/zh active
- 2021-06-10 SI SI202130354T patent/SI4165024T1/sl unknown
- 2021-06-10 CN CN202510007130.6A patent/CN119735588A/zh active Pending
- 2021-06-10 FI FIEP21737878.5T patent/FI4165024T3/fi active
- 2021-06-10 CA CA3183889A patent/CA3183889A1/en active Pending
- 2021-06-10 EP EP25188659.4A patent/EP4653050A3/en active Pending
- 2021-06-10 PT PT217378785T patent/PT4165024T/pt unknown
- 2021-06-10 PE PE2022002892A patent/PE20230860A1/es unknown
- 2021-06-10 UY UY0001039263A patent/UY39263A/es unknown
- 2021-06-10 CN CN202180040963.2A patent/CN115697971B/zh active Active
- 2021-06-10 IL IL326793A patent/IL326793A/en unknown
- 2021-06-10 KR KR1020237000972A patent/KR20230022996A/ko active Pending
- 2021-06-10 DK DK21737878.5T patent/DK4165024T3/da active
- 2021-06-10 ES ES21737878T patent/ES3037072T3/es active Active
- 2021-06-10 LT LTEPPCT/US2021/036896T patent/LT4165024T/lt unknown
- 2021-06-10 IL IL298325A patent/IL298325B1/en unknown
- 2021-06-10 MA MA59968A patent/MA59968B1/fr unknown
- 2021-06-10 HU HUE21737878A patent/HUE072945T2/hu unknown
- 2021-06-10 JO JOP/2022/0334A patent/JOP20220334A1/ar unknown
- 2021-06-10 HR HRP20251229TT patent/HRP20251229T1/hr unknown
- 2021-06-10 PL PL21737878.5T patent/PL4165024T3/pl unknown
- 2021-06-10 AU AU2021288696A patent/AU2021288696A1/en active Pending
- 2021-06-11 US US17/344,947 patent/US20210387978A1/en not_active Abandoned
-
2022
- 2022-12-09 MX MX2025010506A patent/MX2025010506A/es unknown
- 2022-12-09 CO CONC2022/0017903A patent/CO2022017903A2/es unknown
- 2022-12-09 CL CL2022003499A patent/CL2022003499A1/es unknown
-
2025
- 2025-01-28 US US19/039,379 patent/US20250171425A1/en active Pending
- 2025-09-02 JP JP2025145171A patent/JP2025179137A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022017903A2 (es) | Compuestos de dihidroquinolinsulfonamida de ciclobutilo | |
| UY39264A (es) | Compuestos de dihidroquinolinsulfonamida de ciclopropilo | |
| CR20250413A (es) | Compuestos de pirido[4,3–d]pirimidina | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| CL2017002153A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| PE20251236A1 (es) | Formas cristalinas y sales de un agonista del receptor muscarinico | |
| AR035502A1 (es) | Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| UY26919A1 (es) | Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1 | |
| GEAP202516737A (en) | Compounds for treating cancer | |
| MX2025000635A (es) | Compuestos cíclicos y métodos de utilización de estos | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| PE20251750A1 (es) | Inhibidores de hexahidro-2h-pirido[2,1-a]isoquinolina vmat2 y metodos de uso | |
| DOP2025000235A (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| PE20001487A1 (es) | 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles sustituidos con n-(5-fenil-tetrahidrofuranil) metilo y n-(6-fenil-tetrahidropiranil) metilo; procedimientos para prepararlos y su empleo como composiciones farmaceuticas | |
| ECSP22030740A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2025005365A (es) | Compuestos triciclicos | |
| AR134196A1 (es) | Derivados de amidas heteroarílicas como inhibidores de los canales de sodio | |
| PE20252741A1 (es) | Formulaciones de dosis de una sola unidad de alta concentracion y metodos de uso de estas | |
| CO2025004683A2 (es) | Potenciadores novedosos de los canales de potasio sensibles a atp, su preparación y uso | |
| AR129556A1 (es) | Compuestos químicos | |
| AR126260A1 (es) | Moduladores de nlrp3 | |
| AR134195A1 (es) | Derivados de ésteres heteroarílicos como inhibidores de los canales de sodio |